Poolbeg Pharma (POLB) Share Price, News & Analysis

Company Overview

Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro­ and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: 7.60 to 7.80
• 50-Day Range: 7.30 to 10.89
• 52-Week Range: 7.05 to 15.77
• Volume: 970,070 shs
• Average Volume: 1.71 million shs
• Market Capitalization: £38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

POLB Stock Analysis - Frequently Asked Questions

How have POLB shares performed this year?

Poolbeg Pharma's stock was trading at GBX 9.05 at the start of the year. Since then, POLB shares have decreased by 16.0% and is now trading at GBX 7.60.
View the best growth stocks for 2024 here.

How do I buy shares of Poolbeg Pharma?

Shares of POLB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Poolbeg Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Poolbeg Pharma investors own include EQTEC (EQT), Great Western Mining (GWMO), Power Metal Resources (POW), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), Alzamend Neuro (ALZN) and Alpine 4 (ALPP).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:POLB
• CUSIP: N/A
• CIK: N/A
• Web: www.poolbegpharma.com
• Phone: 44 20 7183 1499
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-4,380,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -30.18%
• Return on Assets: -21.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.61
• Quick Ratio: 47.96

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: GBX 3.68 per share
• Price / Cash Flow: 2.11
• Book Value: GBX 3 per share
• Price / Book: 2.58

Miscellaneous

• Outstanding Shares: 500,000,000
• Free Float: N/A
• Market Cap: £38.75 million
• Optionable: Not Optionable
• Beta: 2.11